Alkermes (ALKS) Projected to Post Quarterly Earnings on Wednesday

Alkermes (NASDAQ:ALKS) will likely be posting its quarterly earnings results before the market opens on Wednesday, February 12th. Analysts expect Alkermes to post earnings of $0.81 per share and revenue of $379.74 million for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Alkermes Stock Down 1.1 %

Alkermes stock opened at $31.23 on Tuesday. The stock has a market cap of $5.05 billion, a PE ratio of 16.02, a P/E/G ratio of 1.83 and a beta of 0.49. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.45 and a quick ratio of 3.03. The stock’s fifty day moving average is $30.08 and its two-hundred day moving average is $28.60. Alkermes has a 1-year low of $22.90 and a 1-year high of $32.88.

Insider Buying and Selling

In related news, Director Cato T. Laurencin sold 2,691 shares of Alkermes stock in a transaction on Monday, December 9th. The stock was sold at an average price of $31.85, for a total transaction of $85,708.35. Following the completion of the transaction, the director now directly owns 23,013 shares of the company’s stock, valued at approximately $732,964.05. The trade was a 10.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Christian Todd Nichols sold 5,208 shares of the company’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $29.15, for a total value of $151,813.20. Following the completion of the sale, the senior vice president now directly owns 60,703 shares in the company, valued at $1,769,492.45. This trade represents a 7.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 179,189 shares of company stock valued at $5,723,518 over the last quarter. Company insiders own 4.89% of the company’s stock.

Analyst Ratings Changes

ALKS has been the subject of several recent analyst reports. Mizuho boosted their price objective on shares of Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Cantor Fitzgerald reduced their price objective on Alkermes from $48.00 to $43.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. JPMorgan Chase & Co. lowered their target price on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Piper Sandler reissued an “overweight” rating and set a $37.00 price objective (down from $38.00) on shares of Alkermes in a research report on Friday, October 25th. Finally, The Goldman Sachs Group reduced their target price on shares of Alkermes from $32.00 to $30.00 and set a “buy” rating for the company in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.00.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.